Adalimumab



Description générale

INN	Adalimumab
Codes ATC	L04AB04
Type de médicament	Biological agent
Historique des statuts LME	Ajouté pour la première fois en 2019 (TRS 1021) pour Rheumatoid arthritis Modifié en 2019 (TRS 1021) pour Axial spondyloarthritis Modifié en 2019 (TRS 1021) pour Juvenile idiopathic arthritis Modifié en 2019 (TRS 1021) pour Crohn disease site Modifié en 2025 (TRS 1064) pour Psoriasis of unspecified type
Wikipédia	Adalimumab
DrugBank	Adalimumab

Recommandations

Section Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Rheumatoid arthritis | Axial spondyloarthritis | Crohn disease site

Section Medicines for juvenile joint diseases

- Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

Juvenile idiopathic arthritis

Section Dermatological medicines > Medicines affecting skin differentiation and proliferation

- Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.

Indications

Psoriasis of unspecified type